ENLV vs. APM, FBRX, SLGL, EYEN, ACXP, ALRN, VIRX, UBX, SPRB, and SNSE
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Aptorum Group (APM), Forte Biosciences (FBRX), Sol-Gel Technologies (SLGL), Eyenovia (EYEN), Acurx Pharmaceuticals (ACXP), Aileron Therapeutics (ALRN), Viracta Therapeutics (VIRX), Unity Biotechnology (UBX), Spruce Biosciences (SPRB), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical preparations" industry.
Aptorum Group (NASDAQ:APM) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.
Enlivex Therapeutics has a consensus target price of $7.00, indicating a potential upside of 396.45%. Given Aptorum Group's higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Aptorum Group.
Aptorum Group has higher revenue and earnings than Enlivex Therapeutics.
Enlivex Therapeutics received 8 more outperform votes than Aptorum Group when rated by MarketBeat users. Likewise, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 68.33% of users gave Aptorum Group an outperform vote.
Aptorum Group has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 64.0% of Aptorum Group shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Enlivex Therapeutics had 4 more articles in the media than Aptorum Group. MarketBeat recorded 4 mentions for Enlivex Therapeutics and 0 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.46 beat Enlivex Therapeutics' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.
Enlivex Therapeutics' return on equity of 0.00% beat Aptorum Group's return on equity.
Summary
Enlivex Therapeutics beats Aptorum Group on 7 of the 13 factors compared between the two stocks.
Get Enlivex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
Related Companies and Tools
